Treatment Algorithms for Hormone Receptor–Positive Advanced Breast Cancer: Going Forward in Endocrine Therapy—Overcoming Resistance and Introducing New Agents ER+ breast cancers can exhibit de novo or ...
In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...
Dr. Jaclyn Smeaton, ND A clinical review of the landmark renaming of PCOS to PMOS and why this shift reframes the condition ...
(Beyond Pesticides, February 5, 2024) Public Comment Period Ends February 26, 2024. The U.S. Environmental Protection Agency (EPA) never completed protocol for testing pesticides that disrupt the ...
Many BYU students strive to take care of their health, but their efforts may be thwarted by an item as unassuming as a kitchen skillet. Utahn Cara Clark had two young children when her doctor gave her ...
Endocrine therapy should be considered either alone or in combination with an mTOR inhibitor for the treatment of estrogen receptor/progesterone receptor–positive endometrioid endometrial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results